Allurion Technologies completes patient enrollment in AUDACITY trial

Allurion Technologies announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration approval of the Allurion Balloon. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. “I believe the brisk enrollment in the AUDACITY trial reflects the broad appeal of a novel, completely reversible weight loss device,” said Shelby Sullivan, M.D., Director of the Gastroenterology Metabolic and Bariatric Program at the University of Colorado School of Medicine and Principal Investigator of the AUDACITY trial. “As the obesity epidemic worsens in the United States, I expect options like the Allurion Balloon will be attractive to a large segment of the population.”